Paper41102420
Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight.
Tanaka M and 1 other. Hypertens Res, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight. Papers, record 41102420. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41102420
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glucagon-Like Peptide-1 Receptor Agonists | Major topic |
| Blood Pressure | Major topic |
| Body Weight | Major topic |
| Antihypertensive Agents | Major topic |
| Humans | |
| Animals | |
| Diabetes Mellitus, Type 2 | |
| Hypertension | |
| Hypoglycemic Agents |
Source PubMed
References78
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38832935 | Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. | Cardiovasc Res | 2024 | https://conductscience.org/library/papers/38832935 | PubMed |
| 2 | 25414155 | Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. | Diabetes Care | 2015 | https://conductscience.org/library/papers/25414155 | PubMed |
| 3 | 25882864 | Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients. | J Hypertens | 2015 | https://conductscience.org/library/papers/25882864 | PubMed |
| 4 | 29985448 | Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats. | Hypertens Res | 2018 | https://conductscience.org/library/papers/29985448 | PubMed |
| 5 | 37258623 | Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone? | Hypertens Res | 2023 | https://conductscience.org/library/papers/37258623 | PubMed |
| 6 | 18758869 | Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure. | Obes Surg | 2009 | https://conductscience.org/library/papers/18758869 | PubMed |
| 7 | 27777261 | Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. | Eur J Endocrinol | 2017 | https://conductscience.org/library/papers/27777261 | PubMed |
| 8 | 19776173 | Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. | Am J Physiol Renal Physiol | 2009 | https://conductscience.org/library/papers/19776173 | PubMed |
| 9 | 34170647 | Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34170647 | PubMed |
| 10 | 36964557 | Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. | Cardiovasc Diabetol | 2023 | https://conductscience.org/library/papers/36964557 | PubMed |
| 11 | 22320349 | Investigation of the haemodynamic effects of exenatide in healthy male subjects. | Br J Clin Pharmacol | 2012 | https://conductscience.org/library/papers/22320349 | PubMed |
| 12 | 30473097 | LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. | Mol Metab | 2018 | https://conductscience.org/library/papers/30473097 | PubMed |
| 13 | 26803771 | GLP-1 Agonists and Blood Pressure: A Review of the Evidence. | Curr Hypertens Rep | 2016 | https://conductscience.org/library/papers/26803771 | PubMed |
| 14 | 36196465 | The HOPE Asia network 2022 up-date consensus statement on morning hypertension management. | J Clin Hypertens (Greenwich) | 2022 | https://conductscience.org/library/papers/36196465 | PubMed |
| 15 | 23463656 | Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. | J Clin Endocrinol Metab | 2013 | https://conductscience.org/library/papers/23463656 | PubMed |
| 16 | 26910107 | Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. | Diabetes Obes Metab | 2016 | https://conductscience.org/library/papers/26910107 | PubMed |
| 17 | 26956188 | Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. | Am J Physiol Endocrinol Metab | 2016 | https://conductscience.org/library/papers/26956188 | PubMed |
| 18 | 23653460 | Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. | Endocrinology | 2013 | https://conductscience.org/library/papers/23653460 | PubMed |
| 19 | 21593184 | Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. | Am J Physiol Renal Physiol | 2011 | https://conductscience.org/library/papers/21593184 | PubMed |
| 20 | 28869249 | GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. | Nat Rev Nephrol | 2017 | https://conductscience.org/library/papers/28869249 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42291049 | Maternal cardiometabolic health and the role of GLP-1 receptor agonists from preconception to postpartum: A review of evidence and opportunities. | Am J Prev Cardiol | 2026 | https://conductscience.org/library/papers/42291049 | PubMed |
| 42033464 | Anti-obesity medications in children and adolescents: blood pressure and chronic kidney disease implications. | Pediatr Nephrol | 2026 | https://conductscience.org/library/papers/42033464 | PubMed |
| 41878820 | Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit. | Circ Heart Fail | 2026 | https://conductscience.org/library/papers/41878820 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGT | 183 | PubTator's text mining | https://conductscience.org/library/genes/183 | NCBI Gene |
| GCG | 2641 | PubTator's text mining | https://conductscience.org/library/genes/2641 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41102420
GET https://conductscience.org/api/papers/v1/41102420/references?page=2